Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Monthly injection therapy for HIV found noninferior to daily oral dosing

Publish date:: March 5, 2020

Key clinical point: Monthly intramuscular injections of long-acting cabotegravir and rilpivirine were found to be noninferior to daily oral HIV therapy.

Major finding: At 48 weeks 91% of the patients who switched to long-acting therapy in the FLAIR trial preferred it to their daily oral therapy.

Study details: Two international phase 3 randomized trials assessed more than 1,000 patients.

Disclosures: The ATLAS and FLAIR trials were funded by ViiV Healthcare and Janssen. The authors of both studies reported ties to pharmaceutical associations, and some authors are employees of the two funding sources.

Citation:

Orkin C et al. N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1909512 and Swindells S et al. N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1904398.

This Week's Must Reads

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Three genes could predict congenital Zika infection susceptibility,

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

Must Reads in HIV

Prophylactic HIV treatment in female STI patients is rare,

Opt-out policy at a syringe service program increased HIV/HCV testing,

Social factors predicted peripartum depressive symptoms in Black women with HIV,

Dual therapy serves as well as triple for most HIV patients,

Neural tube defect risk from dolutegravir drops as clinical experience grows,